๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality

โœ Scribed by Ashcroft; Li Wan Po; Williams; Griffiths

Publisher
John Wiley and Sons
Year
1999
Tongue
English
Weight
84 KB
Volume
141
Category
Article
ISSN
0007-0963

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

A comparison of treatment with dithranol
A comparison of treatment with dithranol and calcipotriol on the clinical severity and quality of life in patients with psoriasis
โœ Wall; Poyner; Menday ๐Ÿ“‚ Article ๐Ÿ“… 1998 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 118 KB

In a multicentre, randomized, open study, 306 patients of either sex, over 18 years of age with stable chronic plaque psoriasis > 100 cm2 in surface area, and who gave informed consent, applied Dovonex (calcipotriol) ointment (50 micrograms/g) twice daily or Dithrocream (short-contact dithranol) 0.1

Experiences of stigmatization play a rol
Experiences of stigmatization play a role in mediating the impact of disease severity on quality of life in psoriasis patients
โœ D. Vardy; A. Besser; M. Amir; B. Gesthalter; A. Biton; D. Buskila ๐Ÿ“‚ Article ๐Ÿ“… 2002 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 132 KB

## Background: Psoriasis may have a severe impact on patients' quality of life (qol) in several ways, an impact mediated by the mental or physical difficulties they have to deal with during the course of the disease and the various treatment regimens. in addition, psoriatic patients often suffer fr

Development of process and outcome measu
Development of process and outcome measures for improvement: Lessons learned in a quality improvement collaborative for pediatric inflammatory bowel disease
โœ Wallace V. Crandall; Brendan M. Boyle; Richard B. Colletti; Peter A. Margolis; M ๐Ÿ“‚ Article ๐Ÿ“… 2011 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 320 KB

The Institute of Medicine's publications, To Err is Human and Crossing the Quality Chasm, publicized the widespread deficits in healthcare quality. The quality of care in inflammatory bowel disease (IBD) has not been comprehensively evaluated, in part due to a lack of well-established IBD measures o